Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

2015 Treatment Recommendations for Psoriatic Arthritis

Arthritis & Rheumatology  |  April 28, 2016

Psoriatic arthritis (PsA) is remarkably diverse in presentation and course. To assist clinicians in its management, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published treatment recommendations in 2009 based on a systematic evidence review. To be clinically relevant, such recommendations must be dynamic, and significant developments in PsA pathophysiology and disease assessment, particularly regarding the important contribution of comorbidities coupled with major therapeutic advances, necessitated an update of the GRAPPA recommendations…

Filed under:ConditionsPsoriatic ArthritisResearch Rheum Tagged with:Arthritis & RheumatologyClinical Practice GuidelinesGRAPPAGuidelinesPsoriatic ArthritisResearch

OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2016

Clinical trials have begun to determine if disodium zoledronate tetrahydrate is safe and effective for treating pain in patients with knee osteoarthritis. The FDA has approved the use of ixekizumab for the treatment of plaque psoriasis. And a study has shown that patients with SLE treated with belimumab may be able to decrease steroid use…

Filed under:Biologics/DMARDsDrug Updates Tagged with:belimumabdisodium zoledronate tetrahydrateFDAFood and Drug AdministrationixekizumabKnee Osteoarthritis (OA)Painplaque psoriasissystemic lupus erythematosus (SLE)

The Microbiome in Pediatric Rheumatic Diseases

The Microbiome in Pediatric Rheumatic Diseases

Matthew Stoll, MD, PhD  |  April 15, 2016

The human intestinal microbiota is home to more than 1,000 bacterial species, containing approximately 3 million genes, many of which code for functions that have the potential to affect human physiology.1 Smaller numbers of organisms are also present in the skin, upper gastrointestinal tract, female reproductive tract and the oro- and nasopharynx. As tools have…

Filed under:ConditionsPediatric ConditionsResearch Rheum Tagged with:gastrointestinal diseasejuvenile rheumatoid arthritisMicrobiomemicrobiotiaPediatricResearchRheumatic Disease

Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

Neha Ohri, MD, & Kristine A. Kuhn, MD, PhD  |  April 15, 2016

The microbiome comprises diverse microbial flora, including bacteria, viruses and fungi, that live on mucosal surfaces, predominantly the skin and digestive tract. Microbes evolved billions of years prior to the development of modern Homo sapiens 200,000 years ago; we have always existed with their ubiquitous presence. Despite this, the first microbe was not visualized until…

Filed under:Axial SpondyloarthritisConditionsResearch RheumRheumatoid Arthritis Tagged with:gastrointestinalhealthmicrobialMicrobiomemicrobiotiaResearchRheumatic Disease

Rheumatology Drug Updates: Biosimilars Receive Positive News & More

Michele B. Kaufman, PharmD, BCGP  |  April 13, 2016

On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 On Jan. 16, 2016, EMA granted marketing authorization in the European Union for Benepali to be used to treat rheumatoid arthritis (RA), psoriatic…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:adalimumabApprovalsapremilastBiologicsBiosimilarsdrugEnbreletanerceptFDAHumiraResearchrheumatologySafety

Infliximab Biosimilar Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  April 6, 2016

The FDA has officially approved an infliximab biosimilar for the treatment of multiple autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Prescribing information is now available…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug Administrationinfliximabinfliximab-dyyb

FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Reuters Staff  |  April 6, 2016

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson’s drug Remicade (infliximab), to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. Inflectra, also known as infliximab-dyyb, is expected by some analysts to sell for a 25% discount to Remicade, which generated annual…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAFood and Drug Administrationinfliximabinfliximab-dyyb

Rheumatology Drug Updates: Opioid CR845 for OA Pain; RA Treatments in Development

Michele B. Kaufman, PharmD, BCGP  |  March 15, 2016

CR845—an oral, peripherally selective kappa opioid agonist—is currently in Phase 2 trials for the treatment of pruritus, and acute and chronic pain.1 Eighty patients with hip osteoarthritis (OA) or knee OA were randomized to receive treatment with 0.25 mg, 0.5 mg, 1.0 mg or 5.0 mg CR845 twice daily for two weeks. Safety assessment, pharmacokinetics…

Filed under:AnalgesicsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:drugFDAopioidOsteoarthritisPainRheumatoid arthritisrheumatologySafetytrial

2015 ACR/ARHP Annual Meeting: Skin Issues in Rheumatic Diseases Present Challenges

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

Filed under:ConditionsMeeting ReportsMyositisResearch RheumSystemic Lupus Erythematosus Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)dermatitisDermatologydermatomyositisDiagnosisImmunologyLupusResearchRheumatic DiseaseskinSLEsubacute cutaneous lupus erythematosus

Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2016

Tofacitinib has been released from the FDA’s risk evaluation and mitigation strategy requirement. The FDA is also reviewing a biologics license application for ABP-501, an adalimumab biosimilar. And CHS-0214, a proposed etanercept biosimilar, has met its primary endpoint at Week 24 in an ongoing 52-week study…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabetanerceptFDAFood and Drug AdministrationTofacitinib

  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences